Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CapTere: Capecitabine and Docetaxel in Pancreatic Cancer
NCT00290693Phase 2Completed
- Sponsor
- University of Miami
- Start
- Jul 2004
- Primary completion
- Aug 2008
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine, docetaxel in pancreatic adenocarcinoma (PDAC), sponsored by University of Miami. Started Jul 2004; status: completed.
02
Drugs
capecitabinedocetaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT00290693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00290693.